TRANSDERMALES DELIVERY SYSTEM
(10) (15) RKs 500,095 B8 2007-02-15 correction: Bibl.Daten INID (56)(12) patent specification (48) expenditure day of the correction: 2007-02-15 (21) registration number: A 84/2004 (51) Int. Cl.8: FIG. 4a 1 7COm o>oo o in DVR 0078018 A delivery system for the transdermal administration of active ingredients in the veterinary and human medical fields, which has a cover layer ( 1 ) and is provided with an adhesive ( 2 ) for skin adhesion, the cover layer ( 1 ) being provided with a resealable filling point ( 4, 8 ) for introducing the active ingredient through the cover layer ( 1 ). The resealable filling point ( 4, 8 ) is formed in this case by a valve ( 4 ), preferably a Luer connector ( 4 ) integrated into the cover layer ( 1 ), or by a self-sealing strip ( 8 ) made of rubber and/or mixtures of rubbers, which is integrated into the cover layer ( 1 ) or attached to the cover layer ( 1 ). i.
Delivery system for the transdermalen administration of active substances in Veterinärund humanmedical range, which a surface layer (i) exhibits and provided with an adhesive (2) for the skin adhesion it is characterized, by the fact that the surface layer (I) with a again-lockable filling place (4, 8) for bringing in the active substance by the surface layer (i) is provided.
Delivery system according to requirement I, by the fact characterized that the again-lockable filling place (4, 8) by one into the surface layer (I) integrated is formed or at the surface layer (i) fastened, self-sealing strip (8) from india rubber or mixtures from india rubbers.
Delivery system according to requirement i, by the fact characterized that the again-lockable filling place (4, 8) by into the surface layer (I) integrated valve (4), preferably a Luer connection (4), is formed.
Delivery system after one of the requirements 1 to 3, by the fact characterized that itself to the again-lockable fill-steep (4, 8) at that the skin surface (3) turned side of the surface layer (i) of spacer bars (5) for the Sicherstellung of a defined spacer situation of the surface layer (i) to the skin surface (3) after gluing the delivery system on finds.
Delivery system according to requirement 4, by the fact characterized that the spacer bars (5) at their the skin surface “19…. •. “. ” i…
(3) turned side with one to the surface layer (i) essentially parallel protection panels (6) are taken off.
Delivery system after one of the requirements 1 to 5, by the fact characterized that the surface layer (i) at their the skin surface (3) turned side additionally to a semipermeable diaphragm (7) is fastened, whereby between the surface layer (i) and the diaphragm (7) at least a cavity (i0) is defined.
Delivery system according to requirement 6, by the fact characterized that the cavity (i0) in the comparison to the surrounding atmosphere exhibits a negative pressure.
Delivery system after one of the requirements I to 7, by the fact characterized that the surface layer (i) a foil consisting of a material selected from the group comprehensively polyethylene, laminates from polyethylene and polyester, laminates from polyethylene and a polyester polyethylene terephthalate, with silicone treated polymers, as for instance with silicone treated Polyalkylen terephthalat, or combinations of it is.
Delivery system after one of the requirements i to 8, by the fact characterized that the diaphragm (7) a foil consisting of a material selected from the group comprehensively polyolefins, Polytetramethylen etherterephthalat, polyisoprene, Polyacrylnitril, ethyl propylene copolymers, ethyl vinyl acetate copolymers or other copolymers out ethyl Vinyl methylacetat, ethyl Vinyl ethylacetat, ethyl Vinyl propylacetat or combinations of it are.
• • e De • ù: : ““:. ” '“20 1 [•, .e… i, o “e combination of a delivery system after one of the requirements 1 to 9 with human Gonadotropinen (FSH/LH, hHG, hCG) as active substance.
ii combination of a delivery system after one of the requirements 1 to 9 with the rekombinanten human follicle-stimulating hormone (rFSH) as active substance.
Combination of a delivery system after one of the requirements 1 to 9 with the rekombinanten human luteinisierenden hormone (rLH) as active substance.
Combination of a delivery system after one of the requirements 1 to 9 with the rekombinaten human Choriogonadotropin (rhCG) as active substance.
Combination of a delivery system after requirements 1 to 9 with GnRH Agonisten antagonists as active substance.
one that or GnRHKombination of a delivery system after one of the requirements 1 to 9 with rekombinanten human Gonadotropinen as active substance. 2 3 January. ZOO4 the Rateßanwälte f